Acetyl Tetrapeptide-5
/ Synthetic acetylated tetrapeptide; INCI 'Acetyl Tetrapeptide-5'; periorbital edema / under-eye cosmetic peptideALIAS · Eyeseryl (trade — Lipotec) · Acetyl Tetrapeptide-5 (INCI)
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4 cosmeceutical. INCI catalog peptide marketed under the Eyeseryl trade name (Lipotec / Lubrizol) for periorbital edema and under-eye puffiness. Supplier-published topical clinical material exists; independent Western placebo-controlled replication is limited.
The supplier-stated mechanism is inhibition of angiotensin-converting enzyme (ACE) activity in periorbital microvasculature, with downstream effects on vascular permeability and local fluid retention that are positioned as drivers of under-eye puffiness and dark-circle appearance. Topical penetration of a four-residue peptide to capillary-bed depth is the central uncertainty — formulation (liposomes, gels) is the principal variable in any reported effect.
Tier 4. Supplier-published topical studies (Lipotec / Lubrizol) report reductions in periorbital edema and under-eye dark-circle scoring versus vehicle in subject panels of modest size. PubMed-indexed independent replication is sparse.
Topical application in cosmetic formulations is reported as well tolerated. No systemic exposure has been characterised; ophthalmic safety has not been formally assessed as it would be for a drug product, given the close-to-eye application area.
Regulatory status
- FDA status:
- Not FDA-approved
Industry-authored efficacy framing dominates the published record. The ACE-inhibition mechanism is plausible at the molecular level but is not directly demonstrated in human periorbital tissue post-topical-application. Cosmeceutical positioning is not subject to the FDA drug-efficacy review that would test such mechanism claims.